PortalPublikationen68Ga-FAPI-PET/CT improves diagnostic staging and radiotherap...

68Ga-FAPI-PET/CT improves diagnostic staging and radiotherapy planning of adenoid cystic carcinomas – Imaging analysis and histological validation

Standard

68Ga-FAPI-PET/CT improves diagnostic staging and radiotherapy planning of adenoid cystic carcinomas – Imaging analysis and histological validation. / Röhrich, Manuel; Syed, Mustafa; Liew, Dawn P.; Giesel, Frederik L.; Liermann, Jakob; Choyke, Peter L.; Wefers, Annika K.; Ritz, Thomas; Szymbara, Marina; Schillings, Lisa; Heger, Ulrike; Rathke, Hendrik; Kratochwil, Clemens; Huber, Peter E.; Deimling, Andreas von; Debus, Jürgen; Kauczor, Hans-Ulrich; Haberkorn, Uwe; Adeberg, Sebastian.

in: RADIOTHER ONCOL, Jahrgang 160, 07.2021, S. 192-201.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Röhrich, M, Syed, M, Liew, DP, Giesel, FL, Liermann, J, Choyke, PL, Wefers, AK, Ritz, T, Szymbara, M, Schillings, L, Heger, U, Rathke, H, Kratochwil, C, Huber, PE, Deimling, AV, Debus, J, Kauczor, H-U, Haberkorn, U & Adeberg, S 2021, '68Ga-FAPI-PET/CT improves diagnostic staging and radiotherapy planning of adenoid cystic carcinomas – Imaging analysis and histological validation', RADIOTHER ONCOL, Jg. 160, S. 192-201. https://doi.org/10.1016/j.radonc.2021.04.016

APA

Röhrich, M., Syed, M., Liew, D. P., Giesel, F. L., Liermann, J., Choyke, P. L., Wefers, A. K., Ritz, T., Szymbara, M., Schillings, L., Heger, U., Rathke, H., Kratochwil, C., Huber, P. E., Deimling, A. V., Debus, J., Kauczor, H-U., Haberkorn, U., & Adeberg, S. (2021). 68Ga-FAPI-PET/CT improves diagnostic staging and radiotherapy planning of adenoid cystic carcinomas – Imaging analysis and histological validation. RADIOTHER ONCOL, 160, 192-201. https://doi.org/10.1016/j.radonc.2021.04.016

Vancouver

Röhrich M, Syed M, Liew DP, Giesel FL, Liermann J, Choyke PL et al. 68Ga-FAPI-PET/CT improves diagnostic staging and radiotherapy planning of adenoid cystic carcinomas – Imaging analysis and histological validation. RADIOTHER ONCOL. 2021 Jul;160:192-201. https://doi.org/10.1016/j.radonc.2021.04.016

Bibtex

@article{9d831cf89eb2425497527b547bde9e06,
title = "68Ga-FAPI-PET/CT improves diagnostic staging and radiotherapy planning of adenoid cystic carcinomas – Imaging analysis and histological validation",
abstract = "BackgroundAdenoid cystic carcinomas (ACCs) are rare epithelial tumors mostly situated in the head and neck region and characterized by infiltrative growth. The tumor stroma of ACCs includes cancer-associated fibroblasts (CAFs) expressing Fibroblast Activation Protein (FAP), a new target for positron emission tomography (PET) imaging. Here we describe the value of PET/ computed tomography (PET/CT) imaging using 68Ga-labelled FAP-Inhibitors (68Ga-FAPI-PET/CT) and their clinical potential for staging and radiotherapy planning in 12 ACC patients (7 primary, 5 recurrent).Patients and methodsPatients underwent contrast enhanced staging CT (ceCT) and magnetic resonance imaging (ceMRI) before 68Ga-FAPI - PET/CT. PET-scans were acquired 10, 60 and 180 minutes after administration of 150–250 MBq of 68Ga-labelled FAPI tracers. SUVmax and SUVmean values of ACCs and healthy organs were obtained using a 60% of maximum iso-contour. FAP and alpha smooth muscle actin (α-SMA) immunohistochemistry was performed in 13 cases (3 with and 10 without 68Ga FAPI-PET/CT). Staging and radiotherapy planning based on 68Ga-FAPI-PET/CT versus ceCT/MRI alone were compared.ResultsWe observed elevated tracer uptake in all ACCs. Immunohistochemistry showed FAP-expressing CAFs in the tumor. Compared to conventional staging, 68Ga-FAPI-PET/CT led to upstaging in 2/12 patients and to detection of additional metastases in 3 patients, thus in total 42% of patients had their staging altered. Moreover, 68Ga-FAPI PET improved the accuracy of target volume delineation for radiotherapy, as compared to CT and MRI.Conclusion68Ga-FAPI-PET/CT is a promising imaging modality for ACC, increasing the accuracy of staging exams and radiotherapy planning volumes, as compared conventional to CT and MRI.",
author = "Manuel R{\"o}hrich and Mustafa Syed and Liew, {Dawn P.} and Giesel, {Frederik L.} and Jakob Liermann and Choyke, {Peter L.} and Wefers, {Annika K.} and Thomas Ritz and Marina Szymbara and Lisa Schillings and Ulrike Heger and Hendrik Rathke and Clemens Kratochwil and Huber, {Peter E.} and Deimling, {Andreas von} and J{\"u}rgen Debus and Hans-Ulrich Kauczor and Uwe Haberkorn and Sebastian Adeberg",
year = "2021",
month = jul,
doi = "10.1016/j.radonc.2021.04.016",
language = "English",
volume = "160",
pages = "192--201",
journal = "RADIOTHER ONCOL",
issn = "0167-8140",
publisher = "Elsevier Ireland Ltd",

}

RIS

TY - JOUR

T1 - 68Ga-FAPI-PET/CT improves diagnostic staging and radiotherapy planning of adenoid cystic carcinomas – Imaging analysis and histological validation

AU - Röhrich, Manuel

AU - Syed, Mustafa

AU - Liew, Dawn P.

AU - Giesel, Frederik L.

AU - Liermann, Jakob

AU - Choyke, Peter L.

AU - Wefers, Annika K.

AU - Ritz, Thomas

AU - Szymbara, Marina

AU - Schillings, Lisa

AU - Heger, Ulrike

AU - Rathke, Hendrik

AU - Kratochwil, Clemens

AU - Huber, Peter E.

AU - Deimling, Andreas von

AU - Debus, Jürgen

AU - Kauczor, Hans-Ulrich

AU - Haberkorn, Uwe

AU - Adeberg, Sebastian

PY - 2021/7

Y1 - 2021/7

N2 - BackgroundAdenoid cystic carcinomas (ACCs) are rare epithelial tumors mostly situated in the head and neck region and characterized by infiltrative growth. The tumor stroma of ACCs includes cancer-associated fibroblasts (CAFs) expressing Fibroblast Activation Protein (FAP), a new target for positron emission tomography (PET) imaging. Here we describe the value of PET/ computed tomography (PET/CT) imaging using 68Ga-labelled FAP-Inhibitors (68Ga-FAPI-PET/CT) and their clinical potential for staging and radiotherapy planning in 12 ACC patients (7 primary, 5 recurrent).Patients and methodsPatients underwent contrast enhanced staging CT (ceCT) and magnetic resonance imaging (ceMRI) before 68Ga-FAPI - PET/CT. PET-scans were acquired 10, 60 and 180 minutes after administration of 150–250 MBq of 68Ga-labelled FAPI tracers. SUVmax and SUVmean values of ACCs and healthy organs were obtained using a 60% of maximum iso-contour. FAP and alpha smooth muscle actin (α-SMA) immunohistochemistry was performed in 13 cases (3 with and 10 without 68Ga FAPI-PET/CT). Staging and radiotherapy planning based on 68Ga-FAPI-PET/CT versus ceCT/MRI alone were compared.ResultsWe observed elevated tracer uptake in all ACCs. Immunohistochemistry showed FAP-expressing CAFs in the tumor. Compared to conventional staging, 68Ga-FAPI-PET/CT led to upstaging in 2/12 patients and to detection of additional metastases in 3 patients, thus in total 42% of patients had their staging altered. Moreover, 68Ga-FAPI PET improved the accuracy of target volume delineation for radiotherapy, as compared to CT and MRI.Conclusion68Ga-FAPI-PET/CT is a promising imaging modality for ACC, increasing the accuracy of staging exams and radiotherapy planning volumes, as compared conventional to CT and MRI.

AB - BackgroundAdenoid cystic carcinomas (ACCs) are rare epithelial tumors mostly situated in the head and neck region and characterized by infiltrative growth. The tumor stroma of ACCs includes cancer-associated fibroblasts (CAFs) expressing Fibroblast Activation Protein (FAP), a new target for positron emission tomography (PET) imaging. Here we describe the value of PET/ computed tomography (PET/CT) imaging using 68Ga-labelled FAP-Inhibitors (68Ga-FAPI-PET/CT) and their clinical potential for staging and radiotherapy planning in 12 ACC patients (7 primary, 5 recurrent).Patients and methodsPatients underwent contrast enhanced staging CT (ceCT) and magnetic resonance imaging (ceMRI) before 68Ga-FAPI - PET/CT. PET-scans were acquired 10, 60 and 180 minutes after administration of 150–250 MBq of 68Ga-labelled FAPI tracers. SUVmax and SUVmean values of ACCs and healthy organs were obtained using a 60% of maximum iso-contour. FAP and alpha smooth muscle actin (α-SMA) immunohistochemistry was performed in 13 cases (3 with and 10 without 68Ga FAPI-PET/CT). Staging and radiotherapy planning based on 68Ga-FAPI-PET/CT versus ceCT/MRI alone were compared.ResultsWe observed elevated tracer uptake in all ACCs. Immunohistochemistry showed FAP-expressing CAFs in the tumor. Compared to conventional staging, 68Ga-FAPI-PET/CT led to upstaging in 2/12 patients and to detection of additional metastases in 3 patients, thus in total 42% of patients had their staging altered. Moreover, 68Ga-FAPI PET improved the accuracy of target volume delineation for radiotherapy, as compared to CT and MRI.Conclusion68Ga-FAPI-PET/CT is a promising imaging modality for ACC, increasing the accuracy of staging exams and radiotherapy planning volumes, as compared conventional to CT and MRI.

UR - https://doi.org/10.1016/j.radonc.2021.04.016

U2 - 10.1016/j.radonc.2021.04.016

DO - 10.1016/j.radonc.2021.04.016

M3 - SCORING: Journal article

VL - 160

SP - 192

EP - 201

JO - RADIOTHER ONCOL

JF - RADIOTHER ONCOL

SN - 0167-8140

ER -